Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, et al. Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel, Switzerland). 2022;12(3):586. https://doi.org/10.3390/diagnostics12030586.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Contieri R, Hurle R, Paciotti M, Casale P, Saita A, Porpiglia F, et al. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 patients with NMIBC treated with BCG. Minerva Urol Nefrol. 2023;75(2):180–7. https://doi.org/10.23736/S2724-6051.22.04953-9.

Article  Google Scholar 

Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E, et al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. J Pers Med. 2023;13(3):512. https://doi.org/10.3390/jpm13030512.

Article  PubMed  PubMed Central  Google Scholar 

Ferro M, Chiujdea S, Musi G, Lucarelli G, Del Giudice F, Hurle R, et al. Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis. Clin Genitourin Cancer. 2022;20(2):e166–72. https://doi.org/10.1016/j.clgc.2021.12.005.

Article  PubMed  Google Scholar 

Del Giudice F, Abu-Ghanem Y, Nair R, Mensah E, Kam J, Ibrahim Y, et al. Contemporary trends and predictors associated with adverse pathological upstaging among non-metastatic localized clinical T2 Muscle-invasive bladder cancers undergoing radical cystectomy: outcomes from a single tertiary centre in the United Kingdom. Cancers. 2025;17(9):1477. https://doi.org/10.3390/cancers17091477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Giudice F, Santarelli V, Spurna K, Ali Kirmani SG, Bhatti NH, Abu-Ghanem Y, et al. Contemporary trends and predictors of pT0 in radical cystectomy specimens among non-muscle and muscle-invasive bladder cancer patients: a propensity score-matched analysis from a single tertiary centre in the United Kingdom. Cancers. 2025;17(19):3110. https://doi.org/10.3390/cancers17193110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, et al. Efficacy of different bacillus of Calmette-Guérin (BCG) strains on recurrence rates among intermediate/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis. Cancers. 2023;15(7):1937. https://doi.org/10.3390/cancers15071937.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferro M, Del Giudice F, Carrieri G, Busetto GM, Cormio L, Hurle R, et al. The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis. Cancers. 2021;13(21):5276. https://doi.org/10.3390/cancers13215276.

Article  PubMed  PubMed Central  Google Scholar 

Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, et al. Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. Urol Oncol. 2024;42(3):69.e17-69.e25. https://doi.org/10.1016/j.urolonc.2024.01.001.

Article  PubMed  Google Scholar 

Chen X, He F, Zhang W, Fu Y, Cao Z. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis. Front Oncol. 2023;13:1092969. https://doi.org/10.3389/fonc.2023.1092969.

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Gao L, Wu X, Fan Y, Liu M, Peng L, et al. BCG-induced trained immunity: history, mechanisms and potential applications. J Transl Med. 2023;21(1):106.

Article  PubMed  PubMed Central  Google Scholar 

Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, et al. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611–22. https://doi.org/10.1038/s41585-021-00481-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017;5(1):68. https://doi.org/10.1186/s40425-017-0271-0.

Article  PubMed  PubMed Central  Google Scholar 

Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, et al. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024;133(6):733–41. https://doi.org/10.1111/bju.16293.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Andrea D, Soria F, Grotenhuis AJ, Cha EK, Malats N, Di Stasi S, et al. Association of patients’ sex with treatment outcomes after intravesical Bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer. World J Urol. 2021;39(9):3337–44. https://doi.org/10.1007/s00345-021-03653-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, et al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin. Eur Urol Oncol. 2022;5(1):84–91. https://doi.org/10.1016/j.euo.2021.11.006.

Article  PubMed  Google Scholar 

Flaig TW, Spiess PE, Abern M, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(4):216–25. https://doi.org/10.6004/jnccn.2024.0024. (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 10, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org).

Article  CAS  PubMed  Google Scholar 

D’Andrea D, Mostafid H, Gontero P, Shariat S, Kamat A, Masson-Lecomte A, et al. Unmet need in non-muscle-invasive bladder cancer failing Bacillus Calmette–Guérin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025;8(1):216–29. https://doi.org/10.1016/j.euo.2024.10.012.

Article  PubMed  Google Scholar 

Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617–25. https://doi.org/10.1100/tsw.2006.404.

Article  PubMed  PubMed Central  Google Scholar 

Tabayoyong WB, Kamat AM, O’Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, et al. Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer. Eur Urol Focus. 2021;4(4):512–21. https://doi.org/10.1016/j.euf.2018.08.019.

Article  Google Scholar 

Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer. 2018;18(1):1224. https://doi.org/10.1186/s12885-018-5134-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79. https://doi.org/10.2147/RRU.S63447.

Article  PubMed  PubMed Central  Google Scholar 

Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L. Immunotherapeutic strategies for bladder cancer. Hum Vaccin Immunother. 2014;10(4):977–81. https://doi.org/10.4161/hv.27621.

Article  PubMed  PubMed Central  Google Scholar 

Tan QL, Zhou CY, Cheng L, Luo M, Liu CP, Xu WX, et al. Immunotherapy of Bacillus Calmette-Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg-/- mouse model. Mol Med Rep. 2020;22(1):362–70. https://doi.org/10.3892/mmr.2020.11090.

Article  CAS  PubMed  PubMed Central